Related Experiment Video

Updated: Jul 8, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.6K

Inhibition of Amyloid β-Induced Lipid Membrane Permeation and Amyloid β Aggregation by K162

Dusan Mrdenovic1,2, Piotr Zarzycki3, Marta Majewska1

  • 1Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland.

ACS Chemical Neuroscience
|January 22, 2021
PubMed

Insights

A novel drug candidate, K162, prevents toxic amyloid-beta oligomers from damaging cell membranes in Alzheimer's disease research. This compound offers a new therapeutic avenue by preserving beneficial amyloid-beta monomers.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Alzheimer's disease (AD) involves neurodegeneration driven by amyloid-beta (Aβ) peptide aggregation.
  • Aβ monomers (AβMs) aggregate into toxic Aβ oligomers (AβOs) that can permeate cell membranes, causing damage.

Purpose of the Study:

  • To investigate the effect of the fluorene-based drug candidate K162 on Aβ aggregation and AβO toxicity.
  • To determine if K162 can protect the bilayer lipid membrane (BLM) from AβO-induced damage.

Main Methods:

  • Electrochemical impedance spectroscopy (EIS) to assess membrane integrity.
  • Atomic force microscopy (AFM) to visualize surface changes.
  • Molecular dynamics (MD) simulations to understand molecular interactions.

Main Results:

  • K162 effectively inhibited AβO-induced permeation of the BLM, preserving membrane integrity.
  • K162 treatment resulted in only minor defects on the BLM surface.
  • K162 altered Aβ aggregation, preventing toxic AβO formation and favoring nontoxic AβMs, dimers (AβDs), and fibrils (AβFs).

Conclusions:

  • K162 demonstrates a unique mechanism of inhibiting Aβ aggregation by bypassing toxic oligomer formation.
  • The drug candidate preserves neurologically beneficial AβMs, distinguishing it from other inhibitors.
  • K162 represents a potential alternative therapeutic strategy for Alzheimer's disease.
Keywords:
Alzheimer’s diseaseamyloid βamyloid β aggregationatomic force microscopymembrane permeationtoxicity inhibition

More Related Videos

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.2K
Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

6.2K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...